Source link : https://www.newshealth.biz/health-news/spironolactone-misses-the-mark-in-acute-mi-without-hf/
CHICAGO — A mineralocorticoid receptor antagonist (MRA) was unable to further improve 3-year outcomes of acute myocardial infarction (MI) in the modern era, based on the CLEAR OASIS 9 trial. Among heart attack survivors without heart failure who were on “very good” background medical therapy, routine spironolactone was no better than placebo regarding the trial’s […]
Author : News Health
Publish date : 2024-11-17 22:36:33
Copyright for syndicated content belongs to the linked Source.